Skip to main content

Table 1 The detailed information of MenSCs in the treatment of various diseases

From: Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases

DiseaseDonor ageExperimental methodEffectReference
DMDN/AMurine model, IM, 2 × 107 cellsDifferentiation of myogenic cells after 3 WCui et al. [25]
POFN/AMurine model, IP, 1 × 104 cellsDifferentiation of ovarian granulosa cells after 21 DLiu et al. [36]
T1DMN/AMurine model, IV, 3 × 105 cellsDifferentiation of β-cells after 14 DWu et al. [22]
IUA24–38Murine model, Axillary subcutaneous, 1 × 106 cellsDifferentiation of endometrial cells after 2 WZheng et al. [38]
Sepsis24–38Murine model, IP, 2 × 106 cellsImmunomodulation of lower inflammatory responses after 40 HAlcayaga-Miranda et al. [91]
EC20–40Murine model, IV, 1 × 106 cellsImmunomodulation of regulation of B lymphocytes after 10 DXu et al. [47]
EC20–30Murine model, IV, 1 × 106 cellsImmunomodulation of SDF-1/CXCR4 axis after 10 DLi et al. [48]
Transplant
Vasculopathy
30Murine model, Aorta, 1 × 106 cellsImmunomodulation of B7-H1 expression after 40 DYe et al. [92]
GVHD18–45Murine model, IV, 1 × 106 cellsImmunomodulation of lower peripheral blood mononuclear cells after 14 DLuz-Crawford et al. [45]
IPF20–40Murine model, IV, 1 × 106 cellsImmunomodulation of immunosuppressive and antifibrosis effects after 2 WZhao et al. [49]
Liver fibrosisN/AMurine model, IV, 5 × 105 cellsParacrine effect of secreting MCP-1, IL-6, HGF, GRO, IL-8, and OPG after 2 WChen et al. [18]
MIN/ARat model, IM, 1.5 × 106 cellsParacrine effect of activate AKT, ERK1/2 and STAT3 after 28 DJiang et al. [55]
StrokeN/ARat model, intracerebral, 0.75 × 106 cellsParacrine effect of secreting VEGF, BDNF, and NT-3 after 14 DBorlongan et al. [52]
EOC40Murine model, SC, 2 × 106 cellsParacrine effect of promote foxo3a after 28 DBu et al. [93]
POF40Murine model, IV, 2 × 106 cellsHoming and migration of improving the renewal of germline stem cells after 2 WLai et al. [33]
A549-induced tumor23–42Murine model, intratumoral, 1 × 106 cellsHoming and migration of target tumor sites after 5 DMoreno et al. [83]
POF25–30Murine model, IV, 2 × 106 cellsHoming and migration of improve the ovarian microenvironment after 21 DWang et al. [61]
Cutaneous woundN/AMurine model, intradermal, 1 × 106 cellsImmunosuppressive/paracrine effects after 2 WCuenca et al. [44]
OCD25–45Rabbit model, orthopotic, 7 × 105 cellsDifferentiation/Regenerative capacity after 24 WKhanmohammadi et al. [94]
ALIN/AMurine model, IV, 1 × 106 cellsReduce inflammation/paracrine effect
After 72 H
Ren et al. [95]
Spinal cord injuryN/ARat model, thoracic, 1 × 105 cellsReduce inflammation/paracrine effect after 28 DWu et al. [53]
MIN/ARat model, IM, 1 × 106 cellsSecreting exosomal microrna-21 after 56 DWang et al. [72]
Alzheimer’s diseaseN/AMurine model, hippocampus, 1 × 105 cellsAnti-inflammatory after 7 DZhao et al. [96]
POI25–35Murine model, IV, 1 × 105 cellsRegulating the ECM-dependent FAK/AKT signaling after 40 DFeng et al. [97]
POFN/AMurine model, IV, 1 × 106 cellsInhibiting GADD45b expression in the cell cycle after 28 DGuo et al. [98]
Cervical cancerN/AMurine model, subcutaneous, 5 × 106 cellsMediate TGF-β1-mediated JNK/P21 signaling after 21 DLiu et al. [99]
HCCN/AMurine model, IV, 5 × 105 cellsDNA methylation after 36 DWu et al. [78]
CLIN/ARat model, IM, 1 × 106 cellsSecreting growth factors/inhibiting inflammatory responses after 14 DMurphy et al. [54]
GliomaN/ARat model, Intratumoral, 3 × 106 cellsInhibition of intracranial glioma growth after 14 DHan et al. [100]
Multiple sclerosis18–30Human model, intrathecal, 6 × 106 cellsSuppress immune responses after 12 MZhong et al. [88]
Cardiac fibrosisN/ARat model, IM, 2 × 106 cellsInhibition of endothelial to mesenchymal transition after 7 DZhang et al. [101]
AS20–40Human model, IM, 1 × 106 cellsEnsured embryo implantation after 24 MTan et al. [89]
ALIN/AMurine model, IV, 1 × 106 cellsDownregulation of IL-1 and the upregulation of IL-10 after 48 HXiang et al. [59]
  1. N/A not applicable, IM intramuscular, IP intraperitoneal, IV intravenous, SC subcutaneous, H hour, D day, W week, M month, Ref. reference, DMD Duchenne muscular dystrophy, CLI critical limb ischemia, MI myocardial infarction, POF premature ovarian failure, T1DM type 1 diabetes mellitus, EOC epithelial ovarian cancer, GVHD graft versus host disease, AS Asherman’s syndrome, ALI acute lung injury, EC experimental colitis, IPF Idiopathic pulmonary fibrosis, IUA intrauterine adhesion, POI premature ovarian insufficiency, OCD osteochondral defect, HCC hepatocellular carcinoma